Eight weeks of treatment with human placental extract (HPE) improved menopausal symptoms and fatigue in middle-aged Korean women without affecting their risk profile for cardiovascular disease, according to the results of a small, randomized, placebo-controlled trial.
Eight weeks of treatment with human placental extract (HPE) improved menopausal symptoms and fatigue in middle-aged Korean women without affecting their risk profile for cardiovascular disease, according to the results of a small, randomized, placebo-controlled trial.
For eight weeks, researchers subcutaneously injected either HPE or saline into the abdomens of 84 Korean women aged 40 to 64 years. While the Total Menopause Rating Scale score was similar between the groups at baseline, at 8 weeks the score of the HPE group decreased significantly compared with the placebo group (P=0.033), as did Fatigue Severity Scale and Visual Analog Scale scores (P=0.002 and P=0.001, respectively). Similarly, 17ß-estradiol levels were not significantly different between the groups at baseline, but were significantly higher in the HPE group than in the placebo group at 8 weeks (P=0.031). While this may have positive effects on menopausal symptoms, the authors of the study note that further studies will be needed to determine whether the higher E2 levels associated with HPE contribute to endometrial or breast disease.
Blood pressure, fasting plasma glucose, insulin, insulin resistance index, lipid levels, and high-sensitivity C-reactive protein levels were unaffected.
Kong MH, Lee EJ, Lee SY, et al. Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for cardiovascular disease in middle-aged Korean women. Menopause. 2008;15:296-303.
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More